Clinical trials: Bloodstream Infections
LRTI, Sepsis
Prospective Study to Characterize Host-pathogen Related Factors in Hospitalized and ED Patients With LRTI and/or Sepsis
The TAILORED-Treatment consortium was established to develop new tools aimed to increase the effectiveness of antibiotic and antifungal therapy, reduce adverse events, and help limit the emergence of antimicrobial resistance in…
- Conditions
- LRTI, Sepsis, Fungal Infections, Bacteremia
- Trial name
- TailoredT (NCT02025699)
- Where
- Israel
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- MeMed Diagnostics Ltd.
Infective Endocarditis
Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)
multicenter, randomized, double blind study to describe the safety and efficacy of daptomycin (6 mg/kg q24h) with and without concomitant initial gentamicin combination therapy in the treatment of SAIE
- Trial name
- NCT00638157
- Testing
- daptomycin, daptomycin and gentamicin
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Septic Shock, Endotoxemia
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study
Prospective, multicenter, randomized, open-label study of standard of care plus the PMX cartridge versus standard of care alone in patients with endotoxemic septic shock
- Trial name
- TIGRIS (NCT03901807)
- Testing
- Toraymyxin PMX 20R Extracorporeal Hemoperfusion Cartridge
- Where
- 20 sites in United States
- Volunteers
- 157 people
- Sponsor
- Spectral Diagnostics (US) Inc.
Sepsis Newborn, Malaria
Immune Dysfunction in Newborn Sepsis
The aim of the project is to study neonatal immune dysfunction associated to the risk of newborn sepsis in a malaria endemic area in Benin.
- Conditions
- Sepsis Newborn, Malaria, Immune Responses
- Trial name
- RECIPAL (NCT03780712)
- Testing
- Non applicable
- Volunteers
- 585 people
- Sponsor
- BioMérieux
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia
The purpose of this study is to evaluate the safety, tolerability, efficacy and pharmacokinetics (PK) of CF-301 in addition to background standard of care (SOC) antibacterial therapy for the treatment of Staphylococcus aureus (S.
- Trial name
- NCT03163446
- Testing
- CF-301
- Where
- 78 sites in United States, Belgium and 12 more
- Volunteers
- 121 people
- Sponsor
- ContraFect
Candidemia, Other Forms of Candida Infections(Intra-abdominal Abscess, Peritonitis)
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis® IV
The objective of this study is to collect the safety and efficacy data of Eraxis IV (anidulafungin) 100 mg according to Korea Ministry of Food and Drug Safety regulations.
- Trial name
- NCT00802854
- Where
- 10 sites in South Korea
- Volunteers
- 244 people
- Sponsor
- Pfizer
Sepsis, Severe
Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis Patients
This phase II randomized study will assess the effect of receiving IV recombinant human IL-7 (CYT107) versus placebo in lymphopenic sepsis patients The aim is to confirm the immune cell reconstitution observed in other studies…
- Trial name
- IRIS-7-C&D (NCT03821038)
- Testing
- CYT107
- Where
- 10 sites in United States, France
- Volunteers
- 21 people
- Sponsor
- Revimmune
Sepsis, Bacterial Infections and Mycoses
A Study in Sepsis Patients With Renal Failure
The purpose of this study is to investigate the safety and tolerability of AP in sepsis patients with renal failure and to investigate the effect of AP on inflammatory and clinical parameters in sepsis patients with renal failure.
- Trial name
- NCT00511186
- Testing
- BIAP
- Where
- 9 sites in Belgium, Netherlands
- Volunteers
- 36 people
- Sponsor
- AM-Pharma
Severe Sepsis, Septic Shock
Pharmacogenomic Biomarker Study for Recombinant Human Activated Protein C Treatment in Severe Sepsis
The overall purpose of the study is to determine whether either of the Improved Response Polymorphisms (IRPs) individually predicts a differential DrotAA treatment effect in patients with severe sepsis and high risk of death.
- Trial name
- NCT01486524
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 3,000 people
- Sponsor
- Sirius Genomics Inc.
Septic Shock
Effects of the V1a Agonist FE 202158 in Patients With Septic Shock
The purpose of this trial was to examine the safety and tolerability, pharmacokinetics of FE 202158 and to assess whether it can stabilize blood pressure and reduce vascular (blood vessel) leakage.
- Trial name
- NCT01000649
- Testing
- FE 202158 1.25, FE 202158 2.5, FE 202158 3.75
- Where
- 16 sites in United States, Belgium and 2 more
- Volunteers
- 53 people
- Sponsor
- Ferring Pharmaceuticals
Sepsis
A Phase IIb Study to Determine the Efficacy and Safety of the Study Drug in Patients With Severe Sepsis
The purpose of this study is to determine whether the administration of the study drug is effective in increasing the chance of survival in patients with severe sepsis.
- Trial name
- NCT00034476
- Testing
- sPLA2 Inhibitor
- Where
- 85 sites in United States, Belgium and 3 more
- Volunteers
- 466 people
- Sponsor
- Eli Lilly and Company
Inpatient Hospitalization, Intensive Care Unit Admission, Inpatient Mortality, Sepsis and Septic Shock
Linking Novel Diagnostics With Data-Driven Clinical Decision Support in the Emergency Department
The primary objective of this study is to validate the use of an electronic clinical decision support (CDS) tool, TriageGO with Monocyte Distribution Width (TriageGO-MDW), in the emergency department (ED).
- Trial name
- NCT05335135
- Testing
- TriageGO-MDW Clinical Decision Support, Usual Care
- Where
- 2 sites in United States
- Volunteers
- 300,000 people, healthy volunteers welcome
- Sponsor
- Stocastic, LLC
Sepsis, Infection
The Performance of the Mologic Biomarker Panel in Infection
This study is a prospective, single center, observational, cohort study of patients to determine whether the Mologic Biomarker Panel can identify patients with infection from those without, including those with other reasons for…
- Trial name
- NCT03217552
- Testing
- Mologic Biomarker Panel
- Where
- United Kingdom
- Volunteers
- 600 people
- Sponsor
- Mologic Ltd
Peritonitis, Septic Shock
Effects of Hemoperfusion With a Polymyxin B Membrane in Peritonitis With Septic Shock
The purpose of this randomized, comparative, open and multi-centre study is to show that two sessions of hemoperfusion with Toraymyxin performed within maximum 36 hours after the surgery of a peritonitis by hollow organ…
- Trial name
- ABDO-MIX (NCT01222663)
- Testing
- standard therapy, hemoperfusion
- Where
- 18 sites in France
- Volunteers
- 243 people
- Sponsor
- Meditor SAS
Healthy Volunteer Safety Study
AB103 Peptide Antagonist in Healthy Volunteers
The primary objective of this study is to establish the safety profile and maximum tolerated dose (MTD) of AB103 given as a single intravenous (IV) infusion in healthy volunteers.
- Trial name
- NCT01166984
- Testing
- AB103
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Atox Bio Ltd
Critical Illness, Acute Kidney Injury
Collective Accuryn Physiologic Signals and Signatures
The CAPSS Study is a retrospective and prospective, multi-center, single-arm post-market data collection study with an FDA cleared device.
- Conditions
- Critical Illness, Acute Kidney Injury, Sepsis, Septic Shock
- Trial name
- CAPSS (NCT03817281)
- Testing
- Accuryn Monitoring System
- Where
- United States
- Sponsor
- Potrero Medical
Candidemia, Invasive Candidiasis
CRITIC - Treatment of Candidemia and Invasive Candidiasis
Patients will receive 2mg/kg/day IV daily administration of AmBisome® over 30-60 minutes as a reaction to signs/symptoms and positive Candida culture
- Trial name
- CRITIC (NCT00670657)
- Testing
- AmBisome
- Where
- Italy
- Volunteers
- 39 people
- Sponsor
- Gilead Sciences
Pneumonia, Meningitis
Colombia Epidemiologic Surveillance Study
The study will determine the reduction in invasive pneumococcal disease (IPD) after the introduction of a National Immunization Program with PCV-7 in Bogota.
- Conditions
- Pneumonia, Meningitis, Bacteremia, Sepsis
- Trial name
- LEAP II (NCT00428051)
- Testing
- Surveillance
- Where
- 3 sites in Brazil, Colombia and 1 more
- Volunteers
- 32,867 people
- Sponsor
- Pfizer
Inflammation
Effects of Transvenous Vagus Nerve Stimulation on Immune Response: a Pilot Study
The purpose of this study is to assess the effect of transvenous vagus nerve stimulation (tVNS) on the immune response. In the human endotoxemia model, intravenously administered endotoxin (lipopolysaccharide [LPS]) elicits a…
- Trial name
- NoSIRS (NCT01944228)
- Testing
- Vagal Nerve Stimulation
- Where
- Netherlands
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Monitoring, Physiologic, Vital Signs
Bodytrak® Feasibility Study
Bodytrak® is a wireless earpiece which can monitor the user's vital signs such as tympanic (ear) temperature and heart rate. The earpiece is non-invasive and should fit comfortably within the right ear, similar to an earphone…
- Conditions
- Monitoring, Physiologic, Vital Signs, Sepsis, Altered Level of Consciousness
- Trial name
- NCT03139955
- Testing
- Bodytrak
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Inova Design Solutions Ltd